Evidence map›Paper›PMID 42852629›Full record

ArticleOncology reports2026

Expression of V‑domain Ig suppressor of T cell activation in ovarian cancer and its regulation of follicular regulatory T‑cell function via the AKT/MAPK pathway.

Yan Ma, Yidan Xu, Chunxia Yu, Huatuo Wu, Li Li

Abstract read
PubMed Publisher
In one paragraph

Article in Oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yan MaPostgraduate Department, Affiliated Tumor Hospital of the Third Clinical Medical College, Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region 830011, P.R. China.
Yidan XuPostgraduate Department, Affiliated Tumor Hospital of the Third Clinical Medical College, Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region 830011, P.R. China.
Chunxia YuDepartment of Gynecology, Affiliated Tumor Hospital of the Third Clinical Medical College, Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region 830011, P.R. China.
Huatuo WuPostgraduate Department, Affiliated Tumor Hospital of the Third Clinical Medical College, Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region 830011, P.R. China.
Li LiDepartment of Gynecology, Affiliated Tumor Hospital of the Third Clinical Medical College, Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region 830011, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The high mortality associated with ovarian cancer is closely linked to immune remodeling within the tumor microenvironment (TME). V‑domain Ig suppressor of T cell activation (VISTA), a novel immune checkpoint, has attracted increasing attention in tumor immunology; however, its effects on follicular regulatory T (Tfr) cell function remain unclear. The present study examined VISTA expression in ovarian cancer and explored the correlation between VISTA and alterations in the AKT/MAPK pathway in Tfr‑like cells. Ovarian cancer tissues from different clinical stages and non‑malignant control tissues were analyzed by immunofluorescence, reverse transcription‑quantitative PCR and western blotting to assess VISTA expression and its association with FOXP3

Indexed as

B7 AntigensOvarian NeoplasmsProto-Oncogene Proteins c-aktT-Lymphocytes, RegulatoryAdultCell Line, TumorCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansLymphocyte ActivationMAP Kinase Signaling SystemMiddle AgedTumor MicroenvironmentB7 AntigensProto-Oncogene Proteins c-aktVSIR protein, humanAKT/MAPK signaling pathwayfollicular regulatory T cellsimmune checkpointimmunotherapyovarian cancertumor microenvironmentV‑domain Ig suppressor of T cell activation

Identifiers

PMID42852629

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.